Facebook Linkedin Twitter
Inside Precision Medicine Gilead and Xilio Ink Potential $640M+ Deal around “Next-Generation” Immunotherapy

Gilead Sciences

CART Cell Cancer Immunotherapy
News & Features

Gilead and Xilio Ink Potential $640M+ Deal around “Next-Generation” Immunotherapy

0
Image illustrating man with cardiovascular disease
News & Features

Novo Nordisk Obesity Drug Reduces Risk of Major Adverse Cardiovascular Events by 20 Percent

0
Dentritic Cell activate T cells, trigger immune responses, they are responsible of cells protection of the body.
News & Features

Gilead And EVOQ Ink Deal Worth up to $685M For Autoimmune Diseases

0
T Cells Attacking Cancer Cell
News & Features

Gilead to Purchase Remaining Rights to Potential First-in-Class Immunotherapy from Jounce Therapeutics

0
Stop it
News & Features

FDA Puts Five Trials of Gilead Cancer Candidate Magrolimab on Partial Hold

Alex Philippidis
0
Burkitt's lymphoma cells, is a cancer of the lymphatic system
News & Features

CAR T-Cell Therapy for High-Risk Lymphoma Makes Case as Standard-of-Care Treatment

Chris Anderson
0
FDA’s First COVID-19 Drug Approval Goes to Gilead’s Remdesivir
Coronavirus

FDA’s First COVID-19 Drug Approval Goes to Gilead’s Remdesivir

0
EM Coronavirus, causing SARS
Coronavirus

Combination of Genentech’s Actemra, Gilead’s Remdesivir Enters Phase III Trial for Treatment of Severe COVID-19

0
Senior man lying in hospital bed because of coronavirus infection
Coronavirus

Gilead’s Remdesivir Garners Emergency Use Authorization from FDA for COVID-19

0
Unhealthy Liver Anatomy
Molecular Dx

Gilead Launches Sequencing Spree After Phase III NASH Flop

0

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine